Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 7:03 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,194 matching trials from the live ClinicalTrials.gov search.
Filters: Durham, North Carolina Clear all
Completed Phase 2 Interventional

Safety and Efficacy Study of MRE0094 to Treat Chronic, Neuropathic, Diabetic Foot Ulcers

NCT00312364
View directory record Official record
Conditions
Foot Ulcer, Diabetic, Diabetes Complications
Interventions
MRE0094
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
63
States / cities
Montgomery, Alabama • Bullhead City, Arizona • Phoenix, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Nov 3, 2026, 7:03 PM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Increased Access to Emergency Contraceptive Pills

NCT00060463
View directory record Official record
Conditions
Pregnancy, Sexually Transmitted Diseases
Interventions
Increased access to emergency contraceptive pills
Behavioral
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
14 Years to 24 Years · Female only
Enrollment
1,490 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
2
States / cities
Reno, Nevada • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 7:03 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

FITShop: Promoting Physical Activity in Black Barbershops

NCT01699321
View directory record Official record
Conditions
Physical Activity
Interventions
Your Move (physical activity), Your Money (financial empowerment)
Behavioral · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Male only
Enrollment
628 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 16, 2015 · Synced Nov 3, 2026, 7:03 PM EST
Completed Phase 2Phase 3 Interventional Results available

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

NCT02965378
View directory record Official record
Conditions
FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR3 Gene Amplification, FGFR3 Gene Mutation, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Docetaxel, FGFR Inhibitor AZD4547, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
25 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1083
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 672 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Nov 3, 2026, 7:03 PM EST
Completed Phase 1 Interventional

A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease

NCT00000814
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 20 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
65
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Nov 3, 2026, 7:03 PM EST
Terminated Not applicable Interventional Accepts healthy volunteers

Study of Pregnancy And Neonatal Health (SPAN)

NCT05515744
View directory record Official record
Conditions
Gestational Diabetes Mellitus
Interventions
Childbirth
Procedure
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years and older · Female only
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Chapel Hill, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Nov 3, 2026, 7:03 PM EST
Completed Phase 3 Interventional Results available

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

NCT03930732
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 80 Years
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
51
States / cities
Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Nov 3, 2026, 7:03 PM EST
Terminated Phase 3 Interventional Results available

ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

NCT00879229
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
Ambrisentan, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
51
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Davis, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Nov 3, 2026, 7:03 PM EST
Terminated Phase 1Phase 2 Interventional Results available

E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

NCT01355302
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Previously Untreated Gastric Cancer
Interventions
E7050, cisplatin, capecitabine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Tucson, Arizona • Plantation, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Nov 3, 2026, 7:03 PM EST
Completed Phase 3 Interventional

Using Drug Levels in the Blood to Guide Therapy in HIV Infected Patients Taking a Protease Inhibitor

NCT00041769
View directory record Official record
Conditions
HIV Infections
Interventions
Therapeutic Drug Monitoring (TDM)
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
46
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2010 · Synced Nov 3, 2026, 7:03 PM EST
Active, not recruiting Phase 3 Interventional

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

NCT05633602
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Chemotherapy, Pembrolizumab, Ramucirumab
Drug · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
566
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 442 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Nov 3, 2026, 7:03 PM EST
Completed Phase 3 Interventional Results available

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

NCT01150045
View directory record Official record
Conditions
Colorectal Cancer
Interventions
celecoxib, 5-fluorouracil, placebo, oxaliplatin, leucovorin
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
2,527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
826
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 536 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Nov 3, 2026, 7:03 PM EST
Recruiting Phase 2Phase 3 Interventional

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

NCT03851445
View directory record Official record
Conditions
Previously Treated Non-Small Cell Lung Cancer
Interventions
Screening Platform
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1229
States / cities
Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 807 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Nov 3, 2026, 7:03 PM EST
Completed No phase listed Observational

Long-Term Data Collection From Participants in Adult AIDS Clinical Trials

NCT00001137
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
13 Years and older
Enrollment
5,982 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
75
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2013 · Synced Nov 3, 2026, 7:03 PM EST
Active, not recruiting Not applicable Interventional Results available

Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial

NCT02000115
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Portico transcatheter aortic valve, Commercially available transcatheter aortic valve
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
21 Years and older
Enrollment
1,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Concord, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Nov 3, 2026, 7:03 PM EST
Recruiting Phase 3 Interventional

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

NCT06615050
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux), Cyclophosphamide, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
30
States / cities
Palo Alto, California • San Francisco, California • Miami, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 3, 2026, 7:03 PM EST
Completed Not applicable Interventional Results available

Improving Psychological Distress Among Critical Illness Survivors and Their Caregivers

NCT01983254
View directory record Official record
Conditions
Intensive Care Unit Survivors, Informal Caregivers (Family and Friends)
Interventions
coping skills training, education program
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Chapel Hill, North Carolina • Durham, North Carolina • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Nov 3, 2026, 7:03 PM EST
Completed Phase 1 Interventional

SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy

NCT00000677
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
SCH 39304
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 7:03 PM EST
Completed Phase 2 Interventional

Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas

NCT00003745
View directory record Official record
Conditions
Sarcoma
Interventions
topotecan hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Nov 3, 2026, 7:03 PM EST
Completed No phase listed Observational

A Registry for Patients Taking Uptravi

NCT03278002
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 99 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
84
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Nov 3, 2026, 7:03 PM EST
Recruiting Phase 3 Interventional

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

NCT06056830
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
64Cu-SAR-bisPSMA
Drug
Lead sponsor
Clarity Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 3, 2026, 7:03 PM EST
Terminated Phase 3 Interventional Results available

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

NCT01163253
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,867 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Nov 3, 2026, 7:03 PM EST
Completed Phase 3 Interventional Results available

Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study

NCT03037931
View directory record Official record
Conditions
Heart Failure, Iron-deficiency
Interventions
Ferric Carboxymaltose, Placebo
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,065 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
188
States / cities
Alexander City, Alabama • Auburn, Alabama • Mobile, Alabama + 157 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Nov 3, 2026, 7:03 PM EST
Completed Phase 3 Interventional Results available

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

NCT03057977
View directory record Official record
Conditions
Heart Failure
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
3,730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
92
States / cities
La Mesa, California • Long Beach, California • Los Angeles, California + 81 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Nov 3, 2026, 7:03 PM EST